Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
Juwan Park1, Michael S Lee2, Andrew R Harrison31Department of Ophthalmology, The Catholic University of Korea, Seoul, Korea; 2Department of Ophthalmology, Neurology and Neurosurgery, 3Department of Ophthalmology and Otolaryngology, University of Minnesota, MN, USAAbstract: Even though conventional b...
Enregistré dans:
Auteurs principaux: | Park J, Lee MS, Harrison AR |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/dc46dfaebe1046dda2310de72c92e40d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
par: Jimenez-Shahed J
Publié: (2011) -
Azithromycin in DuraSite® for the treatment of blepharitis
par: Jodi Luchs
Publié: (2010) -
Botulinum toxin injections for blepharospasm prior to ocular surgeries
par: Kaydu E, et autres
Publié: (2012) -
Comparison of ultra-widefield fluorescein angiography with the Heidelberg Spectralis® noncontact ultra-widefield module versus the Optos® Optomap®
par: Witmer MT, et autres
Publié: (2013) -
Comparison of outcomes of conventional WaveLight® Allegretto Wave® and Technolas® excimer lasers in myopic laser in situ keratomileusis
par: Han DC, et autres
Publié: (2012)